CN111032045B - 用于治疗血液病症的丙酮酸激酶激活剂 - Google Patents

用于治疗血液病症的丙酮酸激酶激活剂 Download PDF

Info

Publication number
CN111032045B
CN111032045B CN201880053315.9A CN201880053315A CN111032045B CN 111032045 B CN111032045 B CN 111032045B CN 201880053315 A CN201880053315 A CN 201880053315A CN 111032045 B CN111032045 B CN 111032045B
Authority
CN
China
Prior art keywords
methyl
pharmaceutically acceptable
compound
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880053315.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111032045A (zh
Inventor
G.奇安切塔
刘涛
A.K.帕德亚纳
隋治华
蔡振伟
崔大为
季竞竞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Priority to CN202310962497.4A priority Critical patent/CN117186119A/zh
Publication of CN111032045A publication Critical patent/CN111032045A/zh
Application granted granted Critical
Publication of CN111032045B publication Critical patent/CN111032045B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880053315.9A 2017-08-15 2018-08-15 用于治疗血液病症的丙酮酸激酶激活剂 Active CN111032045B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310962497.4A CN117186119A (zh) 2017-08-15 2018-08-15 用于治疗血液病症的丙酮酸激酶激活剂

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/097496 2017-08-15
CN2017097496 2017-08-15
US201862673533P 2018-05-18 2018-05-18
US201862673526P 2018-05-18 2018-05-18
US62/673,526 2018-05-18
US62/673,533 2018-05-18
PCT/US2018/000128 WO2019035864A1 (en) 2017-08-15 2018-08-15 PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310962497.4A Division CN117186119A (zh) 2017-08-15 2018-08-15 用于治疗血液病症的丙酮酸激酶激活剂

Publications (2)

Publication Number Publication Date
CN111032045A CN111032045A (zh) 2020-04-17
CN111032045B true CN111032045B (zh) 2023-08-15

Family

ID=63524352

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201880053315.9A Active CN111032045B (zh) 2017-08-15 2018-08-15 用于治疗血液病症的丙酮酸激酶激活剂
CN201880053325.2A Active CN111032046B (zh) 2017-08-15 2018-08-15 丙酮酸激酶调节剂及其用途
CN202310962497.4A Pending CN117186119A (zh) 2017-08-15 2018-08-15 用于治疗血液病症的丙酮酸激酶激活剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201880053325.2A Active CN111032046B (zh) 2017-08-15 2018-08-15 丙酮酸激酶调节剂及其用途
CN202310962497.4A Pending CN117186119A (zh) 2017-08-15 2018-08-15 用于治疗血液病症的丙酮酸激酶激活剂

Country Status (34)

Country Link
US (8) US11364240B2 (enExample)
EP (4) EP3668512B1 (enExample)
JP (5) JP7301040B2 (enExample)
KR (3) KR102717594B1 (enExample)
CN (3) CN111032045B (enExample)
AU (4) AU2018316588B2 (enExample)
BR (2) BR112020003254A2 (enExample)
CA (1) CA3072455A1 (enExample)
CL (1) CL2020000375A1 (enExample)
CO (2) CO2020002961A2 (enExample)
CR (1) CR20200123A (enExample)
CY (1) CY1124953T1 (enExample)
DK (2) DK3668512T3 (enExample)
EC (1) ECSP20018487A (enExample)
ES (3) ES2944545T3 (enExample)
FI (1) FI3668512T3 (enExample)
HR (2) HRP20230452T1 (enExample)
HU (2) HUE061910T2 (enExample)
IL (3) IL272599B (enExample)
LT (2) LT3668512T (enExample)
MD (1) MD3668513T2 (enExample)
MX (2) MX2020001832A (enExample)
MY (1) MY204421A (enExample)
PE (1) PE20200724A1 (enExample)
PH (1) PH12020500343B1 (enExample)
PL (2) PL3668512T3 (enExample)
PT (2) PT3668512T (enExample)
RS (2) RS62871B1 (enExample)
SG (2) SG11202001353PA (enExample)
SI (2) SI3668513T1 (enExample)
SM (2) SMT202300146T1 (enExample)
TW (3) TWI796353B (enExample)
UA (1) UA126292C2 (enExample)
WO (3) WO2019035864A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2019000290A1 (en) 2017-03-20 2021-05-07 Forma Therapeutics Inc Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
SG11202001353PA (en) 2017-08-15 2020-03-30 Agios Pharmaceuticals Inc Pyruvate kinase modulators and use thereof
EP3697354A4 (en) 2017-10-20 2021-06-30 The Regents of The University of Michigan EYE DISEASE COMPOSITIONS AND METHODS
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
CA3129829A1 (en) * 2019-02-13 2020-08-20 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
CN114008147B (zh) * 2019-06-26 2023-05-02 日产化学株式会社 电荷传输性清漆
BR112022004715A2 (pt) 2019-09-19 2022-06-14 Forma Therapeutics Inc Composições de ativação de piruvato quinase r (pkr)
EP4185293A4 (en) * 2020-07-21 2025-01-15 The Regents of The University of Michigan COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
US11566030B2 (en) 2021-02-08 2023-01-31 Global Blood Therapeutics, Inc. Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US20240409542A1 (en) * 2021-09-30 2024-12-12 Sitryx Therapeutics Limited Novel compounds
EP4433057A1 (en) * 2021-11-16 2024-09-25 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions
CN116159061A (zh) * 2023-03-09 2023-05-26 上海市第十人民医院 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用
EP4671102A1 (en) 2023-03-28 2025-12-31 Honda Motor Co., Ltd. METHOD FOR PROVIDING INFORMATION, PROGRAM FOR PROVIDING INFORMATION, STORAGE MEDIA AND INFORMATION PROCESSING APPARATUS
WO2024238659A1 (en) 2023-05-15 2024-11-21 Agios Pharmaceuticals, Inc. Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
WO2025010390A1 (en) * 2023-07-05 2025-01-09 Agios Pharmaceuticals, Inc. Synthesis of pyruvate kinase activators
WO2025207563A1 (en) 2024-03-27 2025-10-02 Agios Pharmaceuticals, Inc. Use of a pk activator in the treatment of sickle cell disease

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
CN102159574A (zh) * 2008-07-23 2011-08-17 沃泰克斯药物股份有限公司 三-环吡唑并吡啶激酶抑制剂
CN102448951A (zh) * 2009-04-06 2012-05-09 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
CN103608016A (zh) * 2011-05-03 2014-02-26 安吉奥斯医药品有限公司 丙酮酸激酶激活剂在治疗中的用途
CN103764147A (zh) * 2011-05-03 2014-04-30 安吉奥斯医药品有限公司 用于治疗的丙酮酸激酶活化剂
CN103930422A (zh) * 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
CN104822672A (zh) * 2012-11-08 2015-08-05 安吉奥斯医药品有限公司 治疗性化合物和组合物以及其作为pkm2调节剂的用途
CN105121425A (zh) * 2013-03-15 2015-12-02 安吉奥斯医药品有限公司 治疗性化合物和组合物
CN111032046A (zh) * 2017-08-15 2020-04-17 安吉奥斯医药品有限公司 丙酮酸激酶调节剂及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
HK1049154A1 (zh) 1999-07-30 2003-05-02 Abbott Gmbh & Co. Kg 作为酪氨酸激酶抑制剂的2-吡唑啉-5-酮
CA2381581A1 (en) 1999-09-04 2001-03-15 Astrazeneca Ab Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US8420649B2 (en) * 2008-08-29 2013-04-16 Amgen Inc. Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof
CA3041868C (en) 2008-10-09 2023-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bis sulfonamide piperazinyl and piperidinyl activators of human pyruvatekinase
NZ597379A (en) 2009-06-29 2014-04-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
CA2820408C (en) 2010-12-06 2018-03-06 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
WO2012151450A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
WO2012151448A1 (en) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
US20140249150A1 (en) * 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
EP2877214B1 (en) 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Predicting diabetic complications
CN105008363A (zh) * 2013-01-30 2015-10-28 拜耳医药股份公司 作为mknk-1激酶抑制剂的酰氨基咪唑并哒嗪
HK1220610A1 (zh) 2013-03-13 2017-05-12 弗拉特利发现实验室有限责任公司 哒嗪酮化合物和用於治疗囊肿状纤维化的方法
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
PT3661925T (pt) 2017-07-07 2022-01-31 Inflazome Ltd Novos compostos de sulfonamida-carboxamida
AR112690A1 (es) 2017-08-15 2019-11-27 Agios Pharmaceuticals Inc Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
UY37847A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
EP3652184A1 (en) 2017-08-15 2020-05-20 AbbVie Inc. Macrocyclic mcl-1 inhibitors and methods of use
CA3129829A1 (en) * 2019-02-13 2020-08-20 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
CN102159574A (zh) * 2008-07-23 2011-08-17 沃泰克斯药物股份有限公司 三-环吡唑并吡啶激酶抑制剂
CN102448951A (zh) * 2009-04-06 2012-05-09 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
CN103608016A (zh) * 2011-05-03 2014-02-26 安吉奥斯医药品有限公司 丙酮酸激酶激活剂在治疗中的用途
CN103764147A (zh) * 2011-05-03 2014-04-30 安吉奥斯医药品有限公司 用于治疗的丙酮酸激酶活化剂
CN103930422A (zh) * 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
CN104822672A (zh) * 2012-11-08 2015-08-05 安吉奥斯医药品有限公司 治疗性化合物和组合物以及其作为pkm2调节剂的用途
CN105121425A (zh) * 2013-03-15 2015-12-02 安吉奥斯医药品有限公司 治疗性化合物和组合物
CN111032046A (zh) * 2017-08-15 2020-04-17 安吉奥斯医药品有限公司 丙酮酸激酶调节剂及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase;Jian-kang Jiang等;Bioorganic & Medicinal Chemistry Letters;3387–3393 *

Also Published As

Publication number Publication date
TW201919631A (zh) 2019-06-01
US11872225B2 (en) 2024-01-16
DK3668512T3 (da) 2023-05-22
CR20200123A (es) 2020-06-29
IL292530B2 (en) 2023-06-01
EP3668512A1 (en) 2020-06-24
TWI790271B (zh) 2023-01-21
US20210077490A1 (en) 2021-03-18
US20200206225A1 (en) 2020-07-02
KR102764124B1 (ko) 2025-02-05
US11040036B2 (en) 2021-06-22
US20220233541A1 (en) 2022-07-28
PT3668513T (pt) 2022-01-21
LT3668512T (lt) 2023-06-12
RU2020110573A3 (enExample) 2021-12-24
HUE061910T2 (hu) 2023-08-28
IL272597A (en) 2020-03-31
JP2023027276A (ja) 2023-03-01
MX2020001833A (es) 2020-07-22
CN111032046A (zh) 2020-04-17
EP4026838A1 (en) 2022-07-13
BR112020003254A2 (pt) 2020-10-27
EP3668881B1 (en) 2023-10-04
WO2019035863A8 (en) 2019-03-28
IL272597B (en) 2022-06-01
WO2019035864A8 (en) 2019-03-28
IL292530A (en) 2022-06-01
WO2019035863A1 (en) 2019-02-21
SI3668512T1 (sl) 2023-06-30
HRP20230452T1 (hr) 2023-07-21
JP2023052478A (ja) 2023-04-11
JP2024147805A (ja) 2024-10-16
WO2019035864A1 (en) 2019-02-21
JP7275107B2 (ja) 2023-05-17
CN111032046B (zh) 2023-09-26
DK3668513T3 (da) 2022-01-10
US12133853B2 (en) 2024-11-05
UA126292C2 (uk) 2022-09-14
SG11202001262QA (en) 2020-03-30
WO2019035865A8 (en) 2019-03-28
JP7301040B2 (ja) 2023-06-30
KR102717594B1 (ko) 2024-10-14
AU2023202772A1 (en) 2023-05-18
CN117186119A (zh) 2023-12-08
US20230226055A1 (en) 2023-07-20
TWI823580B (zh) 2023-11-21
FI3668512T3 (fi) 2023-05-12
IL272599A (en) 2020-03-31
PH12020500343B1 (en) 2024-02-21
JP2020531443A (ja) 2020-11-05
SMT202300146T1 (it) 2023-07-20
MX2020001832A (es) 2020-07-22
KR102642408B1 (ko) 2024-02-28
HUE057178T2 (hu) 2022-04-28
CA3071993A1 (en) 2019-02-21
ES2966825T3 (es) 2024-04-24
KR20200054200A (ko) 2020-05-19
AU2024205818A1 (en) 2024-09-05
ES2944545T3 (es) 2023-06-22
KR20200054199A (ko) 2020-05-19
CO2020002961A2 (es) 2020-04-13
US20250144093A1 (en) 2025-05-08
US11957680B2 (en) 2024-04-16
SI3668513T1 (sl) 2022-04-29
RU2020110573A (ru) 2021-09-16
MY204421A (en) 2024-08-28
RS62871B1 (sr) 2022-02-28
ECSP20018487A (es) 2020-05-29
EP3668881A1 (en) 2020-06-24
CA3072455A1 (en) 2019-02-21
SMT202200023T1 (it) 2022-03-21
AU2018316588A1 (en) 2020-02-20
PT3668512T (pt) 2023-05-22
US20220395503A1 (en) 2022-12-15
CL2020000375A1 (es) 2020-12-11
CO2020002959A2 (es) 2020-04-13
MD3668513T2 (ro) 2022-04-30
PL3668512T3 (pl) 2023-06-19
RS64221B1 (sr) 2023-06-30
JP7530453B2 (ja) 2024-08-07
EP3668513A1 (en) 2020-06-24
LT3668513T (lt) 2022-03-25
TW201920203A (zh) 2019-06-01
PL3668513T3 (pl) 2022-03-21
AU2023202772B2 (en) 2024-05-16
CN111032045A (zh) 2020-04-17
US11590132B2 (en) 2023-02-28
US11364240B2 (en) 2022-06-21
PE20200724A1 (es) 2020-07-21
ES2905100T3 (es) 2022-04-07
JP2020531432A (ja) 2020-11-05
AU2018316587B2 (en) 2023-05-11
US20200207785A1 (en) 2020-07-02
US11464775B2 (en) 2022-10-11
AU2018316587A1 (en) 2020-02-20
EP3668513B1 (en) 2021-11-10
TWI796353B (zh) 2023-03-21
AU2018316588B2 (en) 2023-02-02
IL272599B (en) 2022-08-01
HRP20220039T1 (hr) 2022-04-15
PH12020500343A1 (en) 2021-02-08
CY1124953T1 (el) 2023-01-05
EP3668512B1 (en) 2023-02-15
BR112020003262A2 (pt) 2020-09-01
KR20230127364A (ko) 2023-08-31
TW202323258A (zh) 2023-06-16
SG11202001353PA (en) 2020-03-30
WO2019035865A1 (en) 2019-02-21
US20210130371A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
CN111032045B (zh) 用于治疗血液病症的丙酮酸激酶激活剂
HK40077435A (en) Pyruvate kinase activators for use in treating blood disorders
CA3071993C (en) Thiazolo(5',4':4,5)pyrrolo(2,3-d)pyridazine-5-one derivatives and pharmaceutical compositions thereof useful as pyruvate kinase activators for use in treating blood disorders
HK40030323B (en) Pyruvate kinase activators for use in treating blood disorders
EA042084B1 (ru) Активаторы пируваткиназы для применения в лечении нарушений со стороны крови
EA046698B1 (ru) Активаторы пируваткиназы для применения в лечении нарушений со стороны крови

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant